Abstract 580P
Background
Primary tumor location (PTL) is a well-established prognostic factor in stage III and IV colorectal cancer (CRC), with right-sided CRC (RSCC) showing a worse prognosis compared to left-sided CRC (LSCC). However, the impact of PTL on stage II CRC remains uncertain. One explanation for these inconsistencies is the potential confounding effect of molecular biomarkers, such as MMR status. Therefore, there is a need to elucidate the prognostic value of PTL, as well as the role of biomarkers in this effect.
Methods
This study utilized observational data from a retrospective cohort obtained from the Belgian Cancer Registry (BCR). The study population comprised all patients diagnosed with pathologically confirmed stage II CRC in Belgium from January 1st, 2015, to December 31st, 2016 (n= 3,278). Information on PTL, demographics, pathologic T category (pT category), and molecular biomarkers (including MMR status, BRAF and KRAS mutations) was collected from the registry, along with vital status to calculate overall survival (OS). The primary aim of this study was to investigate the independent prognostic value of PTL in stage II CRC. Additionally, we assessed whether potential confounding factors, such as biomarkers and demographics, influenced the prognostic effect of PTL.
Results
In the univariate analysis, patients with stage II RSCC had a significantly worse OS compared to those with LSCC (including rectal cancer; p-value=0.0055 and excluding rectal cancer; p-value=0.0035). Higher age and pT4 were also significantly associated with worse OS. However, in the multivariable analysis, only gender, age, and pathologic T-stage were found to be significant predictors of OS. PTL was not a significant factor in multivariable analysis. Furthermore, biomarkers such as MMR-status, BRAF-, and KRAS mutations did not show a significant effect on OS in either analysis.
Conclusions
Our analysis led us to the conclusion that PTL is not an independent prognostic factor in stage II. Notably, we observed confounding effects between patient characteristics and the prognostic impact of PTL, such as older age at diagnosis and shorter OS in patients with RSCC. Furthermore, molecular biomarkers did not have a statistically significant effect on OS in stage II CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Antwerp.
Funding
Antwerp University Hospital.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
601P - Short-course radiotherapy based total neoadjuvant therapy combined with PD-1 inhibitor for locally advanced rectal cancer: Preliminary findings of TORCH
Presenter: Yaqi Wang
Session: Poster session 10
602P - Brazil-TNT: A randomized phase II trial of neo-adjuvant chemoradiation followed by FOLFIRINOX vs chemoradiation for stage II/III rectal cancer
Presenter: Diogo Bugano Diniz Gomes
Session: Poster session 10
604P - Overall and progression-free survival of patients with metastatic colorectal cancer: A real-world prospective, longitudinal cohort study on the continuum of care (PROMETCO)
Presenter: Miriam Koopman
Session: Poster session 10
605P - First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort
Presenter: HELENA OLIVERES
Session: Poster session 10
606P - Regional lymph nodes (N+ vs N0) in metastatic colorectal cancer
Presenter: Emerik Osterlund
Session: Poster session 10
608P - Resectability of colorectal liver metastases (CLM) with aflibercept plus FOLFIRI: Results from a prospective French cohort
Presenter: René Adam
Session: Poster session 10
609P - The impact of surgical invasiveness on the efficacy of mFOLFOX6 in resected colorectal liver metastasis: An exploratory analysis of JCOG0603
Presenter: Yasuyuki Takamizawa
Session: Poster session 10
610P - Predicting benefit from FOLFOXIRI plus bevacizumab versus FOLFOX/FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer
Presenter: Marinde Bond
Session: Poster session 10
611P - SHR-1701 in combination with BP102 and XELOX as first-line (1L) treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Data from a phase II/III study
Presenter: Rui-Hua Xu
Session: Poster session 10